Analysts expect Biocryst Pharmaceuticals Inc to report revenue of 160.57 M for Q3 26, against a range of 149.75 M to 171.38 M. The most recent reported quarter, Q2 26, came in at 218.25 M, a 26.8% beat against the 172.08 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 117.08 M | 131.53 M | 145.53 M | 163.35 M | 159.40 M | 406.56 M | 156.41 M | 218.25 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 110.97 M | 142.06 M | 145.40 M | 166.29 M | 167.97 M | 156.66 M | 172.14 M | 186.84 M | 171.38 M | 182.59 M | 174.53 M | 214.00 M | 201.12 M | 244.02 M | 184.27 M | 225.77 M | ||||||||||
| Low Estimate | 101.46 M | 131.43 M | 120.37 M | 149.08 M | 142.39 M | 133.79 M | 148.28 M | 157.32 M | 149.75 M | 168.67 M | 144.05 M | 178.43 M | 165.81 M | 220.00 M | 155.82 M | 189.96 M | ||||||||||
| Consensus Estimate | 106.22 M | 136.74 M | 132.88 M | 157.69 M | 155.18 M | 145.23 M | 160.21 M | 172.08 M | 160.57 M | 175.63 M | 159.29 M | 196.22 M | 183.47 M | 232.01 M | 170.04 M | 207.86 M |
Analysts expect Biocryst Pharmaceuticals Inc to report earnings per share of 0.09 for Q3 26, against a range of 0.08 to 0.10. The most recent reported quarter, Q2 26, came in at 0.30, a 100.0% beat against the 0.15 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.07 | -0.13 | 0.00 | 0.02 | 0.06 | 1.12 | -2.98 | 0.30 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.07 | -0.05 | -0.06 | 0.01 | 0.04 | 0.05 | 0.04 | 0.16 | 0.10 | 0.12 | 0.13 | 0.22 | 0.39 | 0.72 | -0.33 | 0.31 | ||||||||||
| Low Estimate | -0.07 | -0.05 | -0.08 | 0.01 | 0.04 | 0.05 | 0.04 | 0.14 | 0.08 | 0.10 | 0.11 | 0.18 | 0.35 | 0.64 | -0.37 | 0.29 | ||||||||||
| Consensus Estimate | -0.07 | -0.05 | -0.07 | 0.01 | 0.04 | 0.05 | 0.04 | 0.15 | 0.09 | 0.11 | 0.12 | 0.20 | 0.37 | 0.68 | -0.35 | 0.30 |
Pull Wall Street consensus for Biocryst Pharmaceuticals Inc (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=BCRX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "BCRX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=BCRX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();